Teladoc, Inc. (NYSE:TDOC) was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating in a research note issued on Wednesday.
A number of other research analysts also recently weighed in on the company. SunTrust Banks, Inc. reaffirmed a “buy” rating and set a $40.00 price target on shares of Teladoc in a research note on Friday, November 3rd. Zacks Investment Research downgraded Teladoc from a “buy” rating to a “hold” rating in a research note on Wednesday, October 18th. Cowen and Company reaffirmed an “outperform” rating and set a $39.00 price target on shares of Teladoc in a research note on Saturday, September 30th. Piper Jaffray Companies reaffirmed a “buy” rating and set a $42.00 price target on shares of Teladoc in a research note on Friday, September 29th. Finally, Cantor Fitzgerald reaffirmed a “hold” rating and set a $31.00 price target on shares of Teladoc in a research note on Tuesday, September 26th. One research analyst has rated the stock with a sell rating, four have given a hold rating and nine have issued a buy rating to the stock. Teladoc currently has an average rating of “Buy” and an average price target of $38.17.
Shares of Teladoc (NYSE:TDOC) traded up $0.65 during trading hours on Wednesday, hitting $28.70. The stock had a trading volume of 895,300 shares, compared to its average volume of 921,261. The company has a debt-to-equity ratio of 0.83, a quick ratio of 5.08 and a current ratio of 5.08. Teladoc has a 12 month low of $15.65 and a 12 month high of $37.55.
Teladoc (NYSE:TDOC) last posted its quarterly earnings results on Wednesday, November 1st. The health services provider reported ($0.55) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.25). Teladoc had a negative return on equity of 21.59% and a negative net margin of 39.61%. The firm had revenue of $68.70 million for the quarter, compared to analyst estimates of $67.53 million. During the same period last year, the company posted ($0.33) earnings per share. The firm’s quarterly revenue was up 112.0% compared to the same quarter last year. equities research analysts forecast that Teladoc will post -1.57 EPS for the current fiscal year.
COPYRIGHT VIOLATION WARNING: This article was originally reported by StockNewsTimes and is the sole property of of StockNewsTimes. If you are reading this article on another site, it was illegally stolen and reposted in violation of US and international copyright law. The original version of this article can be read at https://stocknewstimes.com/2017/11/17/teladoc-inc-tdoc-rating-lowered-to-sell-at-bidaskclub.html.
In other Teladoc news, CEO Jason N. Gorevic sold 20,000 shares of the business’s stock in a transaction that occurred on Monday, October 2nd. The stock was sold at an average price of $33.47, for a total transaction of $669,400.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, VP Mark Hirschhorn sold 10,000 shares of the company’s stock in a transaction that occurred on Monday, October 2nd. The shares were sold at an average price of $34.04, for a total value of $340,400.00. The disclosure for this sale can be found here. Insiders have sold a total of 135,000 shares of company stock valued at $4,408,700 over the last three months. Corporate insiders own 4.47% of the company’s stock.
Hedge funds have recently added to or reduced their stakes in the company. ETF Managers Group LLC bought a new position in shares of Teladoc in the second quarter valued at approximately $104,000. Bank of Montreal Can grew its holdings in shares of Teladoc by 214.2% in the second quarter. Bank of Montreal Can now owns 3,516 shares of the health services provider’s stock valued at $123,000 after acquiring an additional 2,397 shares in the last quarter. Pacad Investment Ltd. bought a new position in shares of Teladoc in the second quarter valued at approximately $135,000. Fred Alger Management Inc. bought a new position in shares of Teladoc in the second quarter valued at approximately $139,000. Finally, Ameritas Investment Partners Inc. grew its holdings in shares of Teladoc by 134.2% in the second quarter. Ameritas Investment Partners Inc. now owns 4,724 shares of the health services provider’s stock valued at $164,000 after acquiring an additional 2,707 shares in the last quarter.
Teladoc Company Profile
Teladoc, Inc is a telehealth company. The Company offers telehealth platform, delivering on-demand healthcare anytime, anywhere, through mobile devices, the Internet, video and phone. The Company’s solution connects its Members, with its over 3,000 board certified physicians and behavioral health professionals treating a range of conditions and cases from acute diagnoses, such as upper respiratory infection, urinary tract infection and sinusitis to dermatological conditions, anxiety and smoking cessation.
Receive News & Ratings for Teladoc Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teladoc Inc. and related companies with MarketBeat.com's FREE daily email newsletter.